Get the Stockscreener App
1.56
3.11%
-0.05
Erasca Inc stock is traded at $1.56, with a volume of 1.01M.
It is down -3.11% in the last 24 hours and up +0.00% over the past month.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.
See More
Previous Close:
$1.61
Open:
$1.59
24h Volume:
1.01M
Relative Volume:
1.05
Market Cap:
$442.53M
Revenue:
-
Net Income/Loss:
$-125.04M
P/E Ratio:
-1.9024
EPS:
-0.82
Net Cash Flow:
$-122.99M
1W Performance:
-3.11%
1M Performance:
+0.00%
6M Performance:
+1.96%
1Y Performance:
-49.02%
1-Day Range:
$1.55
$1.635
1-Week Range:
$1.525
$1.69
52-Week Range:
$1.01
$3.305
Erasca Inc Stock (ERAS) Company Profile
Name
Erasca Inc
Sector
Industry
Phone
(858) 465-6511
Address
3115 MERRYFIELD ROW, SAN DIEGO
Compare ERAS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ERAS
Erasca Inc
|
1.56 | 439.69M | 0 | -125.04M | -122.99M | -0.82 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.53 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.89 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.00 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
756.38 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
324.34 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Erasca Inc Stock (ERAS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-03-25 | Downgrade | BofA Securities | Buy → Underperform |
| Aug-18-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Mar-26-25 | Initiated | Raymond James | Outperform |
| Nov-18-24 | Initiated | Jefferies | Buy |
| Mar-11-24 | Initiated | CapitalOne | Overweight |
| Jan-05-24 | Downgrade | BofA Securities | Buy → Neutral |
| Oct-11-23 | Initiated | H.C. Wainwright | Buy |
| Mar-30-23 | Initiated | Mizuho | Buy |
| Feb-24-23 | Initiated | Goldman | Buy |
| Feb-03-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
View All
Erasca Inc Stock (ERAS) Latest News
Will Erasca Inc. see short term momentumTrade Ideas & Free Verified High Yield Trade Plans - Newser
Custom strategy builders for tracking Erasca Inc.2025 Short Interest & Stepwise Trade Signal Guides - Newser
What’s next for Erasca Inc. stock pricePortfolio Return Summary & Risk Adjusted Buy and Sell Alerts - Newser
Regression analysis insights on Erasca Inc. performancePortfolio Risk Report & AI Driven Stock Movement Reports - Newser
How high can Erasca Inc. stock go2025 Major Catalysts & Daily Volume Surge Trade Alerts - Newser
Analyzing recovery setups for Erasca Inc. investors2025 Market Overview & Community Consensus Stock Picks - Newser
Spotlight On September 2025's Promising Penny Stocks - simplywall.st
Applying chart zones and confluence areas to Erasca Inc.Portfolio Growth Summary & Weekly Sector Rotation Insights - Newser
Using economic indicators to assess Erasca Inc. potentialTrade Signal Summary & Entry Point Strategy Guides - Newser
Market reaction to Erasca Inc.’s recent news2025 Key Highlights & Detailed Earnings Play Alerts - Newser
Is this a good reentry point in Erasca Inc.Market Trend Report & Safe Capital Growth Tips - Newser
Trend analysis for Erasca Inc. this weekMarket Activity Report & Weekly Breakout Stock Alerts - Newser
Tools to monitor Erasca Inc. recovery probability2025 Key Lessons & Detailed Earnings Play Alerts - Newser
Leading vs lagging indicators on Erasca Inc. performanceTrend Reversal & Entry and Exit Point Strategies - Newser
Will Erasca Inc. outperform the marketMarket Trend Summary & Stepwise Swing Trade Plans - Newser
Developing predictive dashboards with Erasca Inc. data2025 Sector Review & Smart Investment Allocation Insights - Newser
Has Erasca Inc. formed a bullish divergence2025 Valuation Update & Precise Buy Zone Identification - Newser
Why Erasca Inc. is moving todayJuly 2025 Intraday Action & Community Consensus Stock Picks - Newser
Risk adjusted return profile for Erasca Inc. analyzedMarket Trend Report & Real-Time Price Movement Reports - Newser
Predicting Erasca Inc. trend using moving averages2025 Technical Patterns & Weekly Return Optimization Plans - Newser
MetLife Investment Management LLC Sells 19,131 Shares of Erasca, Inc. $ERAS - Defense World
Visualizing Erasca Inc. stock with heatmapsEarnings Summary Report & Free Community Consensus Stock Picks - Newser
Applying Elliott Wave Theory to Erasca Inc.2025 Top Gainers & Risk Controlled Daily Trade Plans - Newser
Is Erasca Inc. stock entering bullish territoryMarket Movers & Weekly High Potential Stock Alerts - Newser
Relative strength of Erasca Inc. in sector analysisLong Setup & Consistent Income Trade Ideas - Newser
What to do if you’re stuck in Erasca Inc.Weekly Investment Report & Fast Gain Stock Tips - Newser
Published on: 2025-09-09 05:40:52 - Newser
Erasca, Inc. $ERAS Shares Sold by American Century Companies Inc. - MarketBeat
What the charts say about Erasca Inc. todayWeekly Risk Report & Free Real-Time Volume Trigger Notifications - Newser
Erasca Inc Stock (ERAS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):